Anti-CD1a antibodies for therapeutic application in inflammation, oncology and other diseases

Image from Licence Details: Anti-CD1a antibodies for therapeutic application in inflammation, oncology and other diseases

Applications: Antibodies, therapeutics, dermatology, oncology

Features Benefits
  • High affinity, potent anti-CD1a antibodies that can block and/or deplete CD1a.
  • Well characterised binding sites, structure and function.
  • Humanised versions identified with lead candidates.
  • Extensive unpublished knowledge of the CD1a pathway and disease biology.
  • Strong know-how and vast pathway pipeline.
  • Well established experimental systems.
  • Tested in vitro using the largest bank of human CD1a-reactive T cell clones worldwide.
  • Tested in multiple pre-clinical models
  • Superior to commercially available anti-CD1a antibodies.
  • No other therapeutic anti-CD1a antibodies currently on the market.
  • Potential for additional use in diagnostics and research.
  • Could be used to target inflammation and CD1a-expressing tumours through blocking antibodies, cytotoxic antibodies, drug-conjugated antibodies, bispecific antibodies or CAR-T cells.
  • Meeting an unmet need for broad therapeutic approaches for treatment of inflammatory skin disease, CD1a-expressing cancers and other diseases.

Patented & available for:

  • Licensing
  • Co-development
  • Consulting
Request more information
about this technology

Back to Technologies Available

Sparks Background Image

Ready to get in touch?

Contact Us
Sparks Background Image
© Oxford University Innovation